DOXYCYCLINE- doxycycline capsule Novel Laboratories, Inc.

Doxycycline Capsules, USP Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Doxycycline capsules USP, 50 mg, 75 mg, and 100 mg contain doxycycline monohydrate equivalent to 50 mg, 75 mg, and 100 mg of doxycycline for oral administration. The chemical designation of the light yellow to pale yellow powder is 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,[4S-(4 α ,4 α ,4 α ,5 α ,5 α ,6 α ,12 α)]-,monohydrate.

Structural formula:



 $C_{22}H_{24}N_2O_8 \cdot H_2O$ M.W. = 462.450000

Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Inert ingredients: colloidal silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium starch glycolate; and a hard gelatin capsule which contains titanium dioxide, FD&C Red # 3, D&C Yellow # 10, gelatin, sodium lauryl sulfate, for the 50 mg strength; iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, gelatin, sodium lauryl sulfate for the 75 mg strength and iron oxide black, Iron Oxide Red, Iron Oxide Yellow, Titanium Dioxide, FD & C Red# 3, D&C Yellow # 10, gelatin, sodium lauryl sulfate for the 100 mg strength. The capsules are printed with edible ink containing shellac, titanium dioxide, black iron oxide, brown iron oxide and potassium hydroxide for 50 mg, 75 mg and 100 mg strengths.

CLINICAL PHARMACOLOGY

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:

Time (h	ır): 0.5	1.0	1.5	2.0	3.0	4.0	8.0	12.0	24.0	48.0	72.0
Conc.	1.02	2.26	2.67	3.01	3.16	3.03	2.03	1.62	0.95	0.37	0.15 (mcg/mL)
Average	Average Observed Values										
Maximum Concentration					3.61 n	ncg/mI	(± 0.9	ə sd)			
Time of Maximum Concentration				2.60 hr (± 1.10 sd)							
Elimination Rate Constant				0.049 per hr (± 0.030 sd)							
Half-Li	fe					16.33	3 hr (±	4.53 s	d)		

Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Microbiology:

Mechanism of Action

Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Cross resistance with other tetracyclines is common.

Doxycycline has been shown to be active against most isolates of the following microorganisms, both *in vitro* and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert.

Gram-Negative Bacteria

Acinetobacter species Bartonella bacilliformis

Brucella species

Enterobacter aerogenes

Escherichia coli

Francisella tularensis

Haemophilus ducreyi

Haemophilus influenzae

Klebsiella granulomatis

Klebsiella species

Neisseria gonorrhoeae

Shigella species

Vibrio cholerae

Vibrio fetus

Yersinia pestis

Gram-Positive Bacteria

Bacillus anthracis

Streptococcus pneumoniae

Anaerobes

Clostridium species

Fusobacterium fusiforme

Propionibacterium acnes

Other Bacteria

Norcardiae and other aerobic *Actinomyces* species

Borrelia recurrentis

Chlamydophila psittaci

Chlamydia trachomatis

Mycoplasma pneumoniae

Rickettsiae

Treponema pallidum

Treponema pallidum subspecies pertenue

Ureaplasma urealyticum

Parasites

Balantidium coli

Entamoeba species

Plasmodium falciparum*

*Doxycycline has been found to be active against the asexual erythrocytic forms of *Plasmodium falciparum*, but not against the gametocytes of *P. falciparum*. The precise mechanism of action of the drug is not known.

Susceptibility Testing Methods:

When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution Techniques:

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth and/or agar).^{1,2,4,6,7} The MIC values should be interpreted according to the criteria provided in Table 1.

Diffusion Techniques

Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standard test method. ^{1,3,4} This procedure uses paper disks impregnated with 30 mcg doxycycline to test the susceptibility of bacteria to doxycycline. The disk diffusion interpretive criteria are provided in Table 1.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test

method⁵. The MIC values obtained should be interpreted according to the criteria provided in Table 1.

Bacteria*		nimal Inhibitory ration (mcg per	mL)	Zo	one Diameter (m	im)	Agar Dilution (mcg per mL)		
	S	I	R	S	I	R	S	I	R
Acinetobacter spp.									
Doxycycline	≤4	8	≥16	≥13	10 to 12	≤9	-	-	-
Tetracycline	≤4	8	≥16	≥15	12 to 14	≤11	-	-	-
Anaerobes									
Tetracycline	-	-	-	-	-	-	≤4	8	≥16
Bacillus anthracis†									
Doxycycline	≤1	-	-	-	-	-	-	-	-
Tetracycline	≤1	-	-	-	-	-	-	-	-
Brucella species†									
Doxycycline	≤1	-	-	-	-	-	-	-	-
Tetracycline	≤1	-	-	-	-	-	-	-	-
Enterobacteriaceae									
Doxycycline	≤4	8	≥16	≥14	11 to 13	≤10	-	-	-
Tetracycline	≤4	8	≥16	≥15	12 to 14	≤11	-	-	-
Franciscella tularensis†									
Doxycycline	≤4	-	-	-	-	-	-	-	-
Tetracycline	≤4	-	-	-	-	-	-	-	-
Haemophilus influenzae				-	-	-			
Tetracycline	≤2	4	≥8	≥29	26 to 28	≤25	-	-	-
Mycoplasma pneumoniae†									
Tetracycline	-	-	-	-	-	-	≤2	-	-
Neisseria gonorrhoeae‡									
Tetracycline	-	-	-	≥38	31 to 37	≤30	≤0.25	0.5 to 1	≥2
Norcardiae and other aerobic Actinomyces species									
Doxycycline	≤1	2 to 4	≥8	-	-	-	-	-	-
Streptococcus pneumoniae									
Doxycycline	≤0.25	0.5	>1	>28	25 to 27	<24	-	-	-
Tetracycline	<1	2	>4	>28	25 to 27	<24	-	-	-
Vibrio cholerae									
Doxycycline	≤4	8	≥16	-	-	-	-	-	-
Tetracycline	≤4	8	≥16	-	-	-	-	-	-
Yersinia pestis		-							
Doxycycline	≤4	8	≥16	-	-	_	-	-	-
Tetracycline	_ · ≤4	8	≥16	-	-	_	_	-	-
Ureaplasma urealyticum		Ŭ					1		1
Tetracycline	-	-	-	-	-	-	≤1	-	≥2

Table 1: Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline

* Organisms susceptible to tetracycline are also considered susceptible to doxycycline. However, some organisms that are intermediate or resistant to Tetracycline may be susceptible to doxycycline. † The current absence of resistance isolates precludes defining any results other than "Susceptible". If isolates yielding MIC results other than susceptible, they

should be submitted to a reference laboratory for further testing.

[‡] Gonococci with 30 mcg tetracycline disk zone diameters of < 19 mm usually indicate a plasmid-mediated tetracycline resistant *Neisseria gonorrhoeae* isolate. Resistance in these strains should be confirmed by a dilution test (MIC \geq to 16 mcg / mL).

A report of *Susceptible* (S) indicates that antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen. A report of *Intermediate* (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of *Resistant* (R) indicates that the pathogen is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test^{1,2,3,4,5,6,7}. Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg doxycycline disk the criteria in Table 2 should be achieved.

Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Doxycycline and Tetracycline

QC Strain	Minimal Inhibitory Concentration (mcg/mL)	Zone Diameter (mm)	Agar Dilution (mcg/mL)
Enterococcus faecalis ATCC 29212			
Doxycycline	2 to 8	-	-

Tetracycline	8 to 32	-	-
Escherichia coli ATCC 25922			
Doxycycline	0.5 to 2	18 to 24	-
Tetracycline	0.5 to 2	18 to 25	-
Eggerthella lenta ATCC 43055			
Doxycycline	2 to 16	-	-
Haemophilus influenzae ATCC 49247			
Tetracycline	4 to 32	14 to 22	-
Neisseria gonorrhoeae ATCC 49226			
Tetracycline	-	30 to 42	0.25 to 1
Staphylococcus aureus ATCC 25923			
Doxycycline	-	23 to 29	-
Tetracycline	-	24 to 30	-
Staphylococcus aureus ATCC 29213			
Doxycycline	0.12 to 0.5	-	-
Tetracycline	0.12 to 1	-	-
Streptococcus pneumoniae ATCC 49619			
Doxycycline	0.015 to 0.12	25 to 34	-
Tetracycline	0.06 to 0.5	27 to 31	-
Bacteroides fragilis ATCC 25285			
Tetracycline	-	-	0.12 to 0.5
Bacteroides thetaiotaomicron ATCC 29742	1		
Doxycycline	2 to 8	-	-
Tetracycline	-	-	8 to 32
Mycoplasma pneumoniae ATCC 29342			
Tetracycline	0.06 to 0.5	-	0.06 to 0.5
Ureaplasma urealyticum ATCC 33175			
Tetracycline	-	-	≥8

INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Doxycycline is indicated for the treatment of the following infections:

Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by *Rickettsiae*.

Respiratory tract infections caused by Mycoplasma pneumoniae.

Lymphogranuloma venereum caused by *Chlamydia trachomatis*.

Psittacosis (ornithosis) caused by Chlamydophila psittaci.

Trachoma caused by *Chlamydia trachomatis*, although the infectious agent is not always eliminated as judged by immunofluorescence.

Inclusion conjunctivitis caused by Chlamydia trachomatis.

Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis.

Nongonococcal urethritis caused by Ureaplasma urealyticum.

Relapsing fever due to Borrelia recurrentis.

Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:

Chancroid caused by Haemophilus ducreyi.

Plague due to Yersinia pestis.

Tularemia due to Francisella tularensis.

Cholera caused by Vibrio cholerae.

Campylobacter fetus infections caused by Campylobacter fetus.

Brucellosis due to Brucella species (in conjunction with streptomycin).

Bartonellosis due to Bartonella bacilliformis.

Granuloma inguinale caused by *Calymmatobacterium granulomatis*.

Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:

Escherichia coli

Enterobacter aerogenes

Shigella species

Acinetobacter species

Respiratory tract infections caused by Haemophilus influenzae.

Respiratory tract and urinary tract infections caused by Klebsiella species.

Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

Upper respiratory infections caused by Streptococcus pneumoniae.

Anthrax due to *Bacillus anthracis*, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized *Bacillus anthracis*.

When penicillin is contraindicated, doxycycline is an alternative in the treatment of the following infections:

Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.

Syphilis caused by Treponema pallidum.

Yaws caused by Treponema pertenue.

Listeriosis due to Listeria monocytogenes.

Vincent's infection caused by Fusobacterium fusiforme.

Actinomycosis caused by Actinomyces israelii.

Infections caused by Clostridium species.

In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.

In severe acne, doxycycline may be useful adjunctive therapy.

CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

WARNINGS

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, EXCEPT FOR ANTHRAX, INCLUDING INHALATIONAL ANTHRAX (POST- EXPOSURE), UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline capsules, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile.*

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.

The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

PRECAUTIONS

General:

As with other antibacterial preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.

Intracranial hypertension (IH, pseudotumorcerebri) has been associated with the use of tetracyclines

including doxycycline.Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and doxycyline should be avoided because isotretinoin is also known to cause pseudotumorcerebri.

Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.

Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated.

Prescribing doxycycline capsules in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients:

All patients taking doxycycline should be advised:

-to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (e.g., skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered. (See WARNINGS.)

-to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.)

-that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See Drug Interactions.)

--that the absorption of tetracyclines is reduced when taking bismuth subsalicylate. (See Drug Interactions.)

-not to use outdated or poorly stored doxycycline.

-that the use of doxycycline might increase the incidence of vaginal candidiasis.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Patients should be counseled that antibacterial drugs including doxycycline capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When doxycycline capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline capsules or other antibacterial drugs in the future.

Laboratory Tests:

In venereal disease when coexistent syphilis is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.

In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

Drug Interactions:

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

Drug/Laboratory Test Interactions:

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term studies in animals to evaluate the carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with related antibacterial, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in *in vitro* mammalian cell assays have been reported for related antibacterial (tetracycline, oxytetracycline). Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.

Teratogenic Effects.

Pregnancy Category D:

There are no adequate and well-controlled studies on the use of doxycycline in pregnant short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.⁸

A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. (Sixty-three [0.19%] of the controls and 56 [0.30%] of the cases were treated with doxycycline.) This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases.⁹

A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.¹⁰

Labor and Delivery:

The effect of tetracyclines on labor and delivery is unknown

Nursing Mothers:

Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown.¹¹ Because of the potential for adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See WARNINGS.)

Pediatric Use:

See WARNINGS and DOSAGE AND ADMINISTRATION sections.

ADVERSE REACTIONS

Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.

Gas trointes tinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See DOSAGE AND ADMINISTRATION.)

Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have been reported. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS.)

Renal Toxicity: Rise in BUN has been reported and is apparently dose related. (See WARNINGS.)

Hypersensitivity Reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoidpurpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.

Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines.

Other: Intracranial hypertension (IH, pseudotumorcerebri) has been associated with the use of tetracyclines. (See PRECAUTIONS-General.)

When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.

OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.

DOSAGE AND ADMINISTRATION

THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.

Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50 mg every 6 hours) followed by a maintenance dose of 100 mg/day. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.

For pediatric patients above eight years of age: The recommended dosage schedule for pediatric patients weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses, on subsequent days. For more severe infections up to 2 mg/lb of body weight may be used. For pediatric patients over 100 pounds the usual adult dose should be used.

Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.

Acute epididymo-orchitis caused by *N. gonorrhoeae:* 100 mg, by mouth, twice a day for at least 10 days.

Primary and secondary syphilis: 300 mg a day in divided doses for at least 10 days.

Uncomplicated urethral, endocervical,

or rectal infection in adults caused by *Chlamydia trachomatis:* 100 mg, by mouth, twice a day for at least 7 days.

Nongonococcal urethritis caused by *C. trachomatis* and *U. urealyticum:* 100 mg, by mouth, twice a day for at least 7 days.

Acute epididymo-orchitis caused by *C. trachomatis:* 100 mg, by mouth, twice a day for at least 10 days.

Inhalational anthrax (post-exposure): ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days. CHILDREN: weighing less than 100 pounds (45 kg); 1 mg/lb (2.2 mg/kg) of body weight, by mouth, twice a day for 60 days. Children weighing 100 pounds or more should receive the adult dose.

When used in streptococcal infections, therapy should be continued for 10 days.

Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.) If gastric irritation occurs, doxycycline may be given with food. Ingestion of a high fat meal has been shown to delay the time to peak plasma concentrations by an average of one hour and 20 minutes. However, in the same study, food enhanced the average peak concentration by 7.5% and the area under the curve by 5.7%.

HOW SUPPLIED

Doxycycline Capsules, USP 50 mg have a yellow opaque cap and a white opaque body. The capsules are imprinted "NL 790" with white ink on the cap and "50 mg" with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.

Doxycycline Capsules, USP 50 mg is available in:

Bottles of 50 capsules	NDC 40032-790-11
Bottles of 100 capsules	NDC 40032-790-01
Bottles of 1000 capsules	NDC 40032-790-10

Doxycycline Capsules, USP 75 mg have a brown opaque cap and a white opaque body. The capsules are imprinted "NL 791" with white ink on the cap and "75 mg" with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.

Doxycycline Capsules, USP 75 mg is available in:

Bottles of 50 capsules	NDC 40032-791-11
Bottles of 100 capsules	NDC 40032-791-01
Bottles of 1000 capsules	NDC 40032-791-10

Doxycycline Capsules, USP 100 mg have a brown opaque cap and a yellow opaque body. The capsules are imprinted "NL 792" with white ink on the cap and "100 mg" with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 100 mg doxycycline.

Doxycycline Capsules, USP 100 mg is available in:

Bottles of 50 capsules	NDC 40032-792-11
Bottles of 250 capsules	NDC 40032-792-02
Pottles of 1000 capsules	NDC 40022 702 10

Bottles of 1000 capsulesNDC 40032-792-10

STORE AT 20° to 25°C (68° to 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]

DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER AS DEFINEDIN THE USP/NF. PROTECT FROM LIGHT.

PROTECT FROM LIGHT.

ANIMAL PHARMACOLOGY AND OR TOXICOLOGY

Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO₄, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO₄, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.

Minocycline, tetracycline PO₄, methacycline, doxycycline, tetracycline base, oxytetracyclineHCl and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was

accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.

Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

REFERENCES

1. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing; Twentyfifth Informational Supplement,* CLSI document M100-S25. Clinical and Laboratory Standards Institute, 950 West Valley Road,Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.

2. Clinical and Laboratory Standards Institute. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - 10th ed.* CLSI document M07- A10. Clinical and Laboratory Standards Institute, 950 WestValley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.

3. Clinical and Laboratory Standards Institute.

Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - 11th ed. CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.

4. Clinical and Laboratory Standards Institute.

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition. CLSI document M45-A2. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2010.

5. Clinical and Laboratory Standards Institute (CLSI).

Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eighth Edition. CLSI document M11-A8. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087 USA, 2012.

6. Clinical and Laboratory Standards Institute. *Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard—Second Edition*.CLSI document M24-A2. Clinical and Laboratory Standards Institute, 950West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA. 2011.

7. Clinical and Laboratory Standards Institute.

Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline.CLSI document M43-A. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500,Wayne, Pennsylvania 19087, USA. 2011.

Rx only

Manufactured by:

Novel Laboratories, Inc.

400 Campus Drive


Somerset, NJ0887

PI7920000104


Revised: 02/2016

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Doxycycline Capsules, USP 50 mg 50 count



Doxycycline Capsules, USP 75 mg 100 count



Doxycycline Capsules, USP 100 mg 1000 count



DOXYCY	CLIN	νE						
doxycycline c	apsule							
Product Inf	orma	tion						
Product Type	2		HUMAN PRESCRIPTION DRUG	Ite m C	ode (Source)	NDC:400	32-790	
Route of Adm		tion	ORAL		, ,			
Active Ingr	edien	t/Active Moie	ety					
Ũ		Ingi	redient Name		Basis of S	trength	Strengt	
DOXYCYCLIN	E (UNII:	: N12000U13O) (DOXYCYCLINE ANHYDROUS - UNII:33	348955862) DOXYCYCLINE	ANHYDROUS	50 mg	
Inactive Ing	redie	nts						
			Ingredient Name			S	trength	
SILICON DIO	KIDE (U	NII: ETJ7Z6 XBU	4)					
MAGNESIUM S	STEAR/	ATE (UNII: 70097	7M6I30)					
CELLULOSE,	MICRO	CRYSTALLINE	(UNII: OP1R32D61U)					
SODIUM STAF	RCHGL	YCOLATE TYP	E A POTATO (UNII: 5856J3G2A2)					
TITANIUM DIO	O XIDE (UNII: 15FIX9V2J	P)					
FD&C RED NO	.3 (UN	II: PN2ZH5LOQY)					
D&C YELLOW	/ NO.1	0 (UNII: 35SW5U	SQ3G)					
GELATIN (UNI	I: 2G86	QN327L)						
SODIUM LAU	RYL SU	LFATE (UNII: 36	8GB5141J)					
SHELLAC (UN	II: 46 N1	07B71O)						
FERROSOFER	RIC O	XIDE (UNII: XM0)	M87F357)					
POTASSIUM HYDRO XIDE (UNII: WZH3C48M4T)								
BROWN IRON	OXIDE	E (UNII: 1N032N7	MFO)					
Product Ch								
Color	YELLOW (Opaque Cap), WHITE (Opaque Body) Score no s						e	
Shape	CAPSULE Size 18mm							
	Flavor Imprint Code NL790;50mg							
Contains								
D 1 .								
Packaging								
# Item Co			Package Description		ting Start Date	End Dat		
1 NDC:40032-	790-11	50 in 1 BOTTLE	; Type 0: Not a Combination Product	05/28/2	0 15			

NDA ANDA 2004468 05207.015 OX YC YCLINE SXYCYCIIIC capsule OX YC YCLINE SXYCYCIIIC capsule ORAL INCOMPACING CONCURSION	Marketing Inform Marketing Category ANDA AI OOXYCYCLINE OXYCYCLINE OXYCYCLINE OXYCYCLINE Product Information Product Type Route of Administration Active Ingredient/Ac OOXYCYCLINE (UNII: N120 Inactive Ingredients SILICON DIOXIDE (UNII: N120 Inactive Ingredients SILICON DIOXIDE (UNII: E ELLULOSE, MICROCRY SODIUM STARCH GLYCO OTTANIUM DIOXIDE (UNII: 2G8QN32 SODIUM LAURYL SULFAT FERROSOFERRIC OXIDE FERRIC OXIDE RED (UNII: 46N107B7 POTASSIUM HYDROXIDE	Aation Number or Monograph Citatio Application Number or Monograph Citatio IDA204446 IDA204446 IDA204446 ING PESCRIPTION DRUG IDA204446 ING PESCRIPTION DRUG IDA204446 ING PEGENT Name IDA204446 INI: 70097M6130 IDA204446 INI: 70097M6130 IDA204440 ISFIX9V2JP IDA204440 TJ IDA204440 IUNI: XM0M87F357 IDA204440 IUNI: XM0M87F357 IDA204440 IUNI: XM0M87F357 IDA204440 IUNI: EX43802MRT IDA204440	n Marke 05/28/20	ting Start Date 15 ode (Source) Basis of S	NDC:40032-7 trength Stu ANHYDROUS 75
Na.A Application Number or Monograph Clusion Marketing Start Date Marketing Each Date OXYCYCLINE 0.528/2015 0.528/2015 0.528/2015 Synycycline capaule IRMAN PRESCRIPTION DRUG Rem Code (Source) NDC-40022-791 Note of Administration ORAL 0.528/2015 0.520/2015 NDC-40022-791 Strengt Ingredient Name Basis of Strength Strength OXYCYCLINE (URE NUZOOULDO) (DOXYCYCLINE ANITHOROUS - URE33487558622) DOXYCYCLINE ANITHOROUS - URE33487558622) DOXYCYCLINE ANITHOROUS - URE33487558622) Strength Incore NO NINE (UNE NUZOOULDO) (DOXYCYCLINE ANITHOROUS - URE33487558622) DOXYCYCLINE ANITHOROUS - URE33487558622) Strength Incore NO NINE (UNE NUZOOULDO) (DOXYCYCLINE ANITHOROUS - URE33487558622) INCORE NUZOOULDO) (DOXYCYCLINE ANITHOROUS - URE334875672) INCORE NUZOOULDO (URE SAGE34411) ELLOSOF MARCO ROWYDEL (UNE USEG024017) INCORE 002272) INCORE 002272) INCORE 002272 INCORE 002272) OUDING FAACH (UNE UNE SAGE324877) INCORE 002272 INCORE 002272) INCORE 002272 INCORE 002272 OUDING TAACH (UNE URE SAGE32417) INCORE 002272 INCORE 002272 INCORE 002272 INCORE 002272 REUK COME ENDUE (UNE URE SAGE32417) <td>Marke ting Category ANDA AI OOXYCYCLINE Oxycycline capsule Product Information Product Type Route of Administration Active Ingredient/Ac OXYCYCLINE (UNII: N120 Inactive Ingredients GLICON DIO XIDE (UNII: N120 INACTIVE INGREDIENTIAL (UNII: SELLULO SE, MICRO CRY ODIUM STARCH GLYCO CITANIUM DIO XIDE (UNII: GELATIN (UNII: 2G86QN32 INFERIC OXIDE RED (UNII: SERIC O XIDE RED (UNII: 46107B7 POTASSIUM HYDRO XIDE</td> <td>Inplication Number or Monograph Citatio IDA204446 IDA20440 IDA204446 IDA204464 IDA204464 IDA204464 IDA204464</td> <td>0 5/28/20</td> <td>ode (Source) Basis of S</td> <td>NDC:40032-7 trength Stu ANHYDROUS 75</td>	Marke ting Category ANDA AI OOXYCYCLINE Oxycycline capsule Product Information Product Type Route of Administration Active Ingredient/Ac OXYCYCLINE (UNII: N120 Inactive Ingredients GLICON DIO XIDE (UNII: N120 INACTIVE INGREDIENTIAL (UNII: SELLULO SE, MICRO CRY ODIUM STARCH GLYCO CITANIUM DIO XIDE (UNII: GELATIN (UNII: 2G86QN32 INFERIC OXIDE RED (UNII: SERIC O XIDE RED (UNII: 46107B7 POTASSIUM HYDRO XIDE	Inplication Number or Monograph Citatio IDA204446 IDA20440 IDA204446 IDA204464 IDA204464 IDA204464 IDA204464	0 5/28/20	ode (Source) Basis of S	NDC:40032-7 trength Stu ANHYDROUS 75
Varketing Caregory Application Number or Monograph Clistion Marketing Start Date Marketing End Date NDA ANDA20 4446 0.528 / 2015 Noted Start Date Marketing End Date OXYCYCLINE BUMAN PEESCRPTION DRUG Rem Code (Source) NDC-40022.791 Name of Administration ORA1. NDC-40022.791 NDC-40022.791 Name of Administration NDC-40022.791 NDC-40022.791 NDC-40022.791 NDC-40022.791 NDC-40022.791 NDC-40022.791 <	Marketing Category NDA AI OCXYCYCLINE Dxycycline capsule Product Information Product Type Route of Administration Active Ingredient/Active Ingredient/Active NACTIVE Ingredients ILICON DIO XIDE (UNII: N120 ILICON DIO XIDE (UNII: N120 ILICON DIO XIDE (UNII: N120 ILICON DIO XIDE (UNII: SEARATE (ELLULO SE, MICRO CRY O DIUM STARCH GLYCO TTANIUM DIO XIDE (UNII: ELLATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERROSOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: 46107B7 O TASSIUM HYDRO XIDE	Inplication Number or Monograph Citatio IDA204446 IDA20440 IDA204446 IDA204464 IDA204464 IDA204464 IDA204464	0 5/28/20	ode (Source) Basis of S	NDC:40032-7 trength Stu ANHYDROUS 75
tacketing Care go y Application Number or Monograph Citation NDA ANDA294446 095282015 NCK Citation OXYCYCLINE tray cline capsule NCK Citation CARE Ci	Marketing Category AI NDA AI OXYCYCLINE exycycycline capsule Product Information troduct Type Route of Administration ctive Ingredient/Ac OXYCYCLINE (UNII: N120 nactive Ingredients ILICON DIOXIDE (UNII: N120 nactive Ingredients ILICON DIOXIDE (UNII: CAGNESIUM STEARATE (ELLULOSE, MICROCRY ODIUM STARCH GLYCO TANIUM DIOXIDE (UNII: CEAGAQN32 OIUM LAURYL SULFAT ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: 46)107B7 OTASSIUM HYDROXIDE	Inplication Number or Monograph Citatio IDA204446 IDA20440 IDA204446 IDA204464 IDA204464 IDA204464 IDA204464	0 5/28/20	ode (Source) Basis of S	NDC:40032-7 trength Stu ANHYDROUS 75
OXYCYCLINE xxycycline capsule Product Information MEMAN PRESCREPTION DRUG Rem Code (Source) MDC-40032.791 Surve of Administration OIAL Ingredient/Active Moiety Basis of Strength Strength Ingredient Name Basis of Strength Strength Ingredient Name Strength </td <td>OXYCYCLINE oxycycline capsule Product Information Product Type Route of Administration Active Ingredient/Act OXYCYCLINE (UNII: N120 NACTIVE INGREDIENTIAL NACTIVE INGREDIENTIALIZATION NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION I NACTIVE INGREDIENTIALIZATION I NACTIVE IN NACTIVE NACTIVE INGREDIENTIALIZATION I NACTIVE INGREDIENTIALIZATION I NACTIVE INGREDIENTIALIZATIONE I NACTIVE INGREDIENTIALIZATIONE I NACTIVE INGREDIENTIALIZATIONE I NACTIVE I NA</td> <td>HUMAN PRESCRIPTION DRUG ORAL ORAL ORAL ING redient Name 00U130) (DO XYC YCLINE ANHYDROUS - UNIE 00U130) (DO XYC YCLINE ANHYDROUS - UNIE UNIE: 70097M6130) TALLINE (UNIE: 0P1R32D61U) LATE TYPE A POTATO (UNIE: 5856J3G2A2) 15FIX9 V2JP) 7L) E (UNIE: 368GB5141J) UNIE: XM0 M8 7F357) IK09F3G675) UNIE: EX4380 2MRT)</td> <td>Item Co</td> <td>ode (Source) Basis of S</td> <td>trength Sti ANHYDROUS 75</td>	OXYCYCLINE oxycycline capsule Product Information Product Type Route of Administration Active Ingredient/Act OXYCYCLINE (UNII: N120 NACTIVE INGREDIENTIAL NACTIVE INGREDIENTIALIZATION NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION IN NACTIVE INGREDIENTIALIZATION I NACTIVE INGREDIENTIALIZATION I NACTIVE IN NACTIVE NACTIVE INGREDIENTIALIZATION I NACTIVE INGREDIENTIALIZATION I NACTIVE INGREDIENTIALIZATIONE I NACTIVE INGREDIENTIALIZATIONE I NACTIVE INGREDIENTIALIZATIONE I NACTIVE I NA	HUMAN PRESCRIPTION DRUG ORAL ORAL ORAL ING redient Name 00U130) (DO XYC YCLINE ANHYDROUS - UNIE 00U130) (DO XYC YCLINE ANHYDROUS - UNIE UNIE: 70097M6130) TALLINE (UNIE: 0P1R32D61U) LATE TYPE A POTATO (UNIE: 5856J3G2A2) 15FIX9 V2JP) 7L) E (UNIE: 368GB5141J) UNIE: XM0 M8 7F357) IK09F3G675) UNIE: EX4380 2MRT)	Item Co	ode (Source) Basis of S	trength Sti ANHYDROUS 75
syncycycline capsule roduct Information REMAN PRESCRIPTION DRUG Rem Code (Source) NDC-00022-7911 bane of Administration ORAL ORAL Source) NDC-00022-7911 ctive Ingredient/Active Mole // Ingredient Name Basis of Strength Strength OXYCYCLINE (UME N12000/UISO) (DOXYCYCLINE ANHYDROUS - UNIE3349-55662) DOXYCYCLINE ANHYDROUS - Source) Strength nactive Ingredient/Same Ingredient Name Strength NICON DIO NDE (UME 17726-X014) Ingredient Name Strength NICON DIO NDE (UME 18742-15720-100 Ingredient Name Strength ONUM LAURY LEATE (UME 28660-5141) Ingredient Name Strength ONUM LAURY LEATE (UME 18660-51410)	Product Information Product Type Route of Administration Active Ingredient/Action Active Ingredient/Action Active Ingredients ILICON DIO XIDE (UNII: N120 INACTIVE INGREDIES ILICON DIO XIDE (UNII: COMPARISON ILICON LAURYL SULFAT ERRIC O XIDE RED (UNII: COMPARISON INCOMPARISON	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL		Basis of S	trength Sti ANHYDROUS 75
syncycycline capsule roduct Information REMAN PRESCRIPTION DRUG Rem Code (Source) NDC-00022-7911 bane of Administration ORAL ORAL Source) NDC-00022-7911 ctive Ingredient/Active Mole // Ingredient Name Basis of Strength Strength OXYCYCLINE (UME N12000/UISO) (DOXYCYCLINE ANHYDROUS - UNIE3349-55662) DOXYCYCLINE ANHYDROUS - Source) Strength nactive Ingredient/Same Ingredient Name Strength NICON DIO NDE (UME 17726-X014) Ingredient Name Strength NICON DIO NDE (UME 18742-15720-100 Ingredient Name Strength ONUM LAURY LEATE (UME 28660-5141) Ingredient Name Strength ONUM LAURY LEATE (UME 18660-51410)	Product Information Product Type Route of Administration Active Ingredient/Action Active Ingredient/Action Active Ingredients ILICON DIO XIDE (UNII: N120 INACTIVE INGREDIES ILICON DIO XIDE (UNII: COMPARISON ILICON LAURYL SULFAT ERRIC O XIDE RED (UNII: COMPARISON INCOMPARISON	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL		Basis of S	trength Sti ANHYDROUS 75
syncycycline capsule roduct Information REMAN PRESCRIPTION DRUG Rem Code (Source) NDC-00022-7911 bane of Administration ORAL ORAL Source) NDC-00022-7911 ctive Ingredient/Active Mole // Ingredient Name Basis of Strength Strength OXYCYCLINE (UME N12000/UISO) (DOXYCYCLINE ANHYDROUS - UNIE3349-55662) DOXYCYCLINE ANHYDROUS - Source) Strength nactive Ingredient/Same Ingredient Name Strength NICON DIO NDE (UME 17726-X014) Ingredient Name Strength NICON DIO NDE (UME 18742-15720-100 Ingredient Name Strength ONUM LAURY LEATE (UME 28660-5141) Ingredient Name Strength ONUM LAURY LEATE (UME 18660-51410)	Product Information Product Type Route of Administration Active Ingredient/Action Active Ingredient/Action Active Ingredients ILICON DIO XIDE (UNII: N120 INACTIVE INGREDIES ILICON DIO XIDE (UNII: COMPARISON ILICON LAURYL SULFAT ERRIC O XIDE RED (UNII: COMPARISON INCOMPARISON	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL		Basis of S	trength Sti ANHYDROUS 75
Induct Type IRUMAN PRESCRIPTION DRUG Not-40032-791 issue of Administration ORAL ORAL Basis of Strength Strength introduct Type Ingredient Mame Basis of Strength Strength OXYCYCLINE (UNE NIZODULSO) (DOXYCYCLINE ANNYDROUS - UNRE340955862) DOXYCYCLINE ANNYDROUS - UNRE340955862) DOXYCYCLINE ANNYDROUS - UNRE340955862) Strength Incredient S Ingredient Mame Strength Strength Incredient S Ingredient Mame Ingredient Mame Incredient S Ingredient Mame Strength Incredient S Ingredient Mame Ingredient Mame Incredient S Ingredient Mame Mathematica Ingredient Mame Incredient S Ingredient Mame Mathematica Ingredient Mame Intrautin Mitter Strege Strengt S Ingred	Product Type Route of Administration Active Ingredient/Act OXYCYCLINE (UNII: N120 nactive Ingredients ILICON DIOXIDE (UNII: E ILICON DIOXIDE (UNII: E ELAUIN STARCH GLYCO ODIUM STARCH GLYCO ODIUM STARCH GLYCO ODIUM STARCH GLYCO ITANIUM DIOXIDE (UNII: ELATIN (UNII: 2G86QN32 ODIUM LAURYL SULFAT ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: ERRIC OXIDE RED (UNII: ERRIC OXIDE YELLOW (HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL		Basis of S	trength Sti ANHYDROUS 75
Induct Type IRIMAN PRESCRIPTION DRUG NDC-40032-791 State of Administration ORAL ORAL Basis of Strength Normality Ingredient/Active Molecy Ingredient Name Basis of Strength Strength OXYCYCLINE (UNE: NI2000UISO) (DOXYCYCLINE ANNYDROUS - UNRE348955862) DOXYCYCLINE ANNYDROUS - UNRE348955862) DOXYCYCLINE ANNYDROUS - UNRE348955862) Strength Inclose Interconcervision Ingredient Name Strength Strength Introduct Type Ingredient Name Ingredient Name Strength Introduct Name Ingredient Name Strength Ingredient Name Ingredient Name Introduct Type Ingredient Name Ingredient Name Strength Introduct Govern Statune (Nume 1998) Ingredient Name Ingredient Name Ingredient Name Introduct Govern Statune (Nume 1998) Ingredient Name Ingredient Name Ingredient Name Introduct Govern Statune (Nume 1998) Ingredient Name Ingredient Name Ingredient Name Introduct Govern Statune (Nume 1998) Ingredient Name Ingredient Name Ingredient Name Introduct Govern Statune (Nume 1998) Ingredient Name Ingredient Name Ingredient Name Introduct Govern Statune (Nume 2016) Ingredient Name Ingredient Name Ingredient Name	Product Type Route of Administration Active Ingredient/Act OXYCYCLINE (UNII: N120 nactive Ingredients ILICON DIO XIDE (UNII: E IAGNESIUM STARCH GLYCO ODIUM STARCH GLYCO ODIUM STARCH GLYCO ODIUM STARCH GLYCO ODIUM LAURYL SULFAT ERROSOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLOW (HELLAC (UNII: 46 N107B7 OTASSIUM HYDRO XIDE	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL		Basis of S	trength Sti ANHYDROUS 75
RAIL RAIL Impredient/Active Moiety Impredient/Active Moiety Impredient/Active Moiety Impredient Name Basis of Strength Strength Impredient Name Strength Impredit Name <td>Active Ingredient/Active Ingredient/Active Ingredient/Active Ingredient/Active Ingredients ILICON DIO XIDE (UNII: N120 INGRESIUM STEARATE (IELLULOSE, MICROCRY ODIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: IELATIN (UNII: 2G86QN32 ODIUM LAURYL SULFAT ERROSOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLOW (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE</td> <td>ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL</td> <td></td> <td>Basis of S</td> <td>trength Sti ANHYDROUS 75</td>	Active Ingredient/Active Ingredient/Active Ingredient/Active Ingredient/Active Ingredients ILICON DIO XIDE (UNII: N120 INGRESIUM STEARATE (IELLULOSE, MICROCRY ODIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: IELATIN (UNII: 2G86QN32 ODIUM LAURYL SULFAT ERROSOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLOW (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL		Basis of S	trength Sti ANHYDROUS 75
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Ingredient Name CAVEVELINE (UNE N2000UJDO) (DOXYEVELINE ANINDROUS - UNE3348955862) DOXYEVELINE ANINDROUS 75 mg Inactive Ingredients Ingredient Name Ingredients Ingredient Name Ingredient N	Active Ingredient/Active Ingredient/Active Ingredients OXYCYCLINE (UNII: N120 nactive Ingredients ILICON DIOXIDE (UNII: E IAGNESIUM STEARET ELLULOSE, MICROCRY ODIUM STARCH GLYCO ITANIUM DIOXIDE (UNII: ELATIN (UNII: 2G86QN32 ODIUM LAURYL SULFAT ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: ERRIC OXIDE RED (UNII: ERRIC OXIDE YELLOW (HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE	ive Moiety Ingredient Name 00U130) (DOXYCYCLINE ANHYDROUS - UNIE Ingredient Name Ingredient Name IJ7Z6 XBU4) JNIE: 70097M6130) TALLINE (UNIE: 0P1R32D61U) LATE TYPE A POTATO (UNIE: 5856J3G2A2) 15FIX9V2JP) 7L) TE (UNIE: 368GB5141J) UNIE: XM0 M8 7F357) UK09F3G675) UNIE: EX43802MRT)	3348955862		ANHYDROUS 75
Ingredient Name Basis of Strength Strength OXYCYCLINE (UNE NI2000UISO) (DOXYCYCLINE ANIN'DROUS - UNE348955862) DOXYCYCLINE ANIN'DROUS - UNE348955862) DOXYCYCLINE ANIN'DROUS - UNE348955862) DOXYCYCLINE ANIN'DROUS - UNE348955862) DOXYCYCLINE ANIN'DROUS - UNE348955862) Strength ILCON DIO XIDE (UNE ENT756 XBU4) Ingredient Name Strength Ingredient Name Ingredint Name Ingredint Name	O XYCYCLINE (UNII: N120 nactive Ingredients ILICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULO SE, MICRO CRY O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SO FERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46 N107B7 O TASSIUM HYDRO XIDE	Ingredient Name 00U130) (DOXYCYCLINE ANHYDROUS - UNIE 00U130) (DOXYCYCLINE ANHYDROUS - UNIE 00U130) (DOXYCYCLINE ANHYDROUS - UNIE 00U130) 00U130 0000 0000 0000 0000 0000 0000 00	3348955862		ANHYDROUS 75
Ingredient Name Basis of Strength Strength OXYCYCLINE (UNE NI2000UI30) (DXYCYCLINE ANNYDROUS - UNE34895882) DOXYCYCLINE ANNYDROUS - Strength nactive Ingredients Ingredient Name Strength ILGON DID XIDE (UNE ET7758 X8U4) Ingredient Name Strength MAGNESIUM STEARATE (UNE 70097M6 BD) Ingredient Name Ingredient Name ILGON DID XIDE (UNE ET7758 X8U4) Ingredient Name Ingredient Name ILGON DID XIDE (UNE ET7758 X8U4) Ingredient Name Ingredient Name ILGON DID XIDE (UNE ET7758 X8U4) Ingredient Name Ingredient Name ILGON DID XIDE (UNE INSPORTSON INCOME VIEW SU2P) Ingredient Name Ingredient Name State Diversity SULFAITE (UNE Not SUBSON INCOME VIEW SU2P) Ingredient Name Ingredient Name State Diversity SULFAITE (UNE Not SUB CONTERVENT) Ingredient Name Ingredient Name State Diversity SULFAITE (UNE Not SUB CONTERVENT) Ingredient Name Ingredient Name State Diversity SULFAITE (UNE Not SUB CONTERVENT) Ingredient Name Ingredient Name State Diversity SULFAITE (UNE NOT SUB CONTERVENT) Ingredient Name Ingredient Name State Diversity Support (One Name Prist)	O XYCYCLINE (UNII: N120 nactive Ingredients ILICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULO SE, MICRO CRY O DIUM STARCH GLYCO TTANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SO FERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46 N107B7 O TASSIUM HYDRO XIDE	Ingredient Name 00U130) (DOXYCYCLINE ANHYDROUS - UNIE 00U130) (DOXYCYCLINE ANHYDROUS - UNIE 00U130) (DOXYCYCLINE ANHYDROUS - UNIE 00U130) 00U130 0000 0000 0000 0000 0000 0000 00	3348955862		ANHYDROUS 75
OXYCYCLINE (UNE NI2000U30) (DOXYCYCLINE ANHYDROUS - UNIE3348955862) DOXYCYCLINE ANHYDROUS '75 mg Ingredient Name Strength ILCON DIO XIDE (UNE FED7265 XBUJ Strength ILCON DIO XIDE (UNE FED7265 XBUJ) Strength ILCON DIO XIDE (UNE FED7265 XBUJ) Strength ILCON DIO XIDE (UNE FED7265 XBUJ) Strength ILCON DIO XIDE (UNE SES63503C2A2) Strength Strength Strength Strength <t< td=""><td>nactive Ingredients ILICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULOSE, MICROCRY O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SO FERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE</td><td>Ingredient Name IJ726 XBU4) INII: 70097M6130) IXILINE (UNII: OP1R32D6 1U) LATE TYPE A POTATO (UNII: 5856J3G2A2) I5FIX9 V2JP) 7L) IE (UNII: 368GB5141J) UNII: XM0 M87F357) IK09F3G675) UNII: EX43802MRT)</td><td>3348955862</td><td></td><td>ANHYDROUS 75</td></t<>	nactive Ingredients ILICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULOSE, MICROCRY O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SO FERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	Ingredient Name IJ726 XBU4) INII: 70097M6130) IXILINE (UNII: OP1R32D6 1U) LATE TYPE A POTATO (UNII: 5856J3G2A2) I5FIX9 V2JP) 7L) IE (UNII: 368GB5141J) UNII: XM0 M87F357) IK09F3G675) UNII: EX43802MRT)	3348955862		ANHYDROUS 75
Ingredient Name Strength LLCON DIO XIDE (UNIE E1726 XBU4) Acknesulus TEARATE (UNIE 0097Ms E00) ELLULOSE, MICRO CRYSTALINE (UNIE 0918206 IU) ODUM STARCIG CLYCOLATE TYPE A POTATO (UNIE 585933G2A2) TANUM DIO XDE (UNIE 15R18 9421P) ELATIN (UNIE 2080 Q0327.1) OBUM LAURYL SULFATE (UNIE 36656141) ERRIC O XDE (UNIE 1K0976675)	LICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULOSE, MICROCRY O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	TJ726 XBU4) JNII: 70097M6130) STALLINE (UNII: OP1R32D61U) LATE TYPE A POTATO (UNII: 5856J3G2A2) 15FIX9V2JP) 7L) TE (UNII: 368GB5141J) UNII: XM0M87F357) IK09F3G675) UNII: EX43802MRT)			Stren
Ingredient Name Strength LLCON DIO XIDE (UNE ET1726 XBU4) <	ILICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULO SE, MICRO CRY O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SO FERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	TJ726 XBU4) JNII: 70097M6130) STALLINE (UNII: OP1R32D61U) LATE TYPE A POTATO (UNII: 5856J3G2A2) 15FIX9V2JP) 7L) TE (UNII: 368GB5141J) UNII: XM0M87F357) IK09F3G675) UNII: EX43802MRT)			Stren
Ingredient Name Strength LLCON DIO XIDE (UNE ET1726 XBU4) <	ILICON DIO XIDE (UNII: E IAGNESIUM STEARATE (ELLULO SE, MICRO CRY O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERRO SO FERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	TJ726 XBU4) JNII: 70097M6130) STALLINE (UNII: OP1R32D61U) LATE TYPE A POTATO (UNII: 5856J3G2A2) 15FIX9V2JP) 7L) TE (UNII: 368GB5141J) UNII: XM0M87F357) IK09F3G675) UNII: EX43802MRT)			Stren
AGA DESIGN STEARATE (UNB: 70:097AE B0) Image: Control of Contro	IAGNESIUM STEARATE (ELLULOSE, MICROCRY ODIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 ODIUM LAURYL SULFAT ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: ERRIC OXIDE RED (UNII: ERRIC OXIDE YELLOW HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE	UNII: 70097M6130) STALLINE (UNII: OP1R32D61U) LATE TYPE A POTATO (UNII: 5856J3G2A2) 15FIX9V2JP) 7L) TE (UNII: 368GB5141J) UNII: XM0M87F357) 1K09F3G675) UNII: EX438O2MRT)			
ELLULOSE, MICRO CRYSTALLINE (UNE: OPIR3206 IU) ODIUM STARCIG GLYCOLATE TYPE A POTATO (UNE: S856/J3G2A2) TANUM PIO XOLE (UNE: SFRN 2021P) ELATIN (UNE: 2G80Q N327.) ELATIN (UNE: 2G80Q N327.) ELATIN (UNE: SUE FRR 20 (UNE: S46 GB 5/41.) ERRO SO FERRIC OXIDE (UNE: S46 GB 5/41.) ERRO SO FERRIC OXIDE (UNE: S46 GB 5/41.) ERRO SO TALE RED (UNE: S46 GB 5/41.) ERRO SO RED (UNE: S46 GB 5/41.) FILLAC (UNE: 46 N10 78/10.) O TASSUM HYDRO XDE (UNE: S47 GB 4.4 M4T) RO SAUDE (UNE: 100 32N/MFO) TO ASSUM HYDRO XDE (UNE: S47 GB 4.4 M4T) RO SAUDE (UNE: 100 32N/MFO) TO ASSUM HYDRO XDE (UNE: W2H5C48 M4T) RO SUBO SUBE (UNE: 100 32N/MFO) TO ASSUM HYDRO XDE (UNE: 100 100 100 100 100 100 100 100 100 10	ELLULOSE, MICROCRY ODIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 ODIUM LAURYL SULFAT ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: ERRIC OXIDE RELLOW (HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE	STALLINE (UNII: OP1R32D6 1U) LATE TYPE A POTATO (UNII: 5856J3G2A2) 15FIX9 V2JP) 7L) TE (UNII: 368GB5141J) UNII: XM0 M87F357) IK09F3G675) UNII: EX438O2MRT)			
ODIUM STARCH GLYCOLATE TYPE A POTATO (UME 5856/3/32/2) Image: State	O DIUM STARCH GLYCO ITANIUM DIO XIDE (UNII: ELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFA ERROSOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	LATE TYPE A POTATO (UNI: 5856J3G2A2) 15FIX9V2JP) 7L) TE (UNII: 368GB5141J) UNII: XM0M87F357) 1K09F3G675) UNII: EX438O2MRT)			
TTANIUM DIO XIDE (UNIE 15FX39/21P)	ITANIUM DIO XIDE (UNII: BELATIN (UNII: 2G86QN32 O DIUM LAURYL SULFAT ERROSOFERRIC O XIDE ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLO W (HELLAC (UNII: 46N107B7 O TASSIUM HYDRO XIDE	15FIX9 V2JP) 7L) TE (UNII: 368 GB5141J) UNII: XM0 M8 7F357) IK09 F3G6 75) UNII: EX438 O2MRT)			
ODIUM LAURYL SULFATE (UNIE 368 GB5141)) Image: State St	ODIUM LAURYL SULFAT ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: ERRIC OXIDE YELLOW (HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE	E (UNII: 368GB5141J) UNII: XM0M87F357) IK09F3G675) UNII: EX438O2MRT)			
ERRIC O XIDE (UNIE: KM0 MB 7F357) ERRIC O XIDE (RED (UNIE: KM0 9F3675) ERRIC O XIDE (RED (UNIE: EX4380 O2MRT) HELLAC (UNIE 46N107B710) OTASSIUM HYDRO XIDE (UNIE: UX9EG48 M4T) ROWN IRON O XIDE (UNIE: IN032N7MFO) OTASSIUM HYDRO XIDE (UNIE: IN032N7MFO) Product Characteristics Froduct Characteristics CAPSUE USE CAPSUE USE (UNIE: IN032N7MFO) Ange CAPSUE USE (UNIE: IN032N7MFO) Size IIII (INIE: IN032N7MFO) Ange CAPSUE USE (INIE: IN032N7MFO) Ange CAPSUE (INIE: IN032N7MFO) Ange CAPSUE USE (INIE: INIE: INI	ERROSOFERRIC OXIDE ERRIC OXIDE RED (UNII: ERRIC OXIDE YELLOW (HELLAC (UNII: 46 N107B7 OTASSIUM HYDROXIDE	UNII: XM0 M8 7F357) IK0 9F3G6 75) UNII: EX438 O 2MRT)			
ERRIC OXIDE RED (UNIE: 1K09F3G675) ERRIC OXIDE YELLOW (UNIE: EX4802DMRT) HELLAC (UNIE: 46N107B710) OTASSIUM HYDROX DIE (UNIE: WZHBC48 M4T) IROWN IRON OXIDE (UNIE: 1N032N7MFO) Product Characteristics Solor WHTE (Opaque Body), BROWN (Opaque Cap) Score no score hape CAPSULE STORY (Opaque Cap) Size 18mm Imprint Code I8mm Imprint Code NL79 L75mg Product Order Score NL79 L75mg NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 0528/2015 NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 0528/2015 NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 0528/2015 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA204446 NDC:40032-791-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 0528/2015 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA204446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing End Da NDA ANDA20446 VARKeting Category Application Number or Monograph Citation Marketing End Da VARKeting Category Application	ERRIC O XIDE RED (UNII: ERRIC O XIDE YELLOW (HELLAC (UNII: 46 N107B7 O TASSIUM HYDRO XIDE	1K09F3G675) UNII: EX438O2MRT)			
ERRIC OXIDE YELLOW (UNE: EX438020RT) → · · · · · · · · · · · · · · · · · ·	ERRIC OXIDE YELLOW (HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE	UNII: EX438O2MRT)			
HELLAC (UNIE 40 N107B710) Image: Colspan="4">Colspan="4"Colspan="4"Colspan="4"Colspan="4"Colspan="4"	HELLAC (UNII: 46N107B7 OTASSIUM HYDROXIDE				
RROWN IRON O XIDE (UNIE: IN0.32N7/MFO) Product Characteristics Color WHTTE (Opaque Body), BROWN (Opaque Cap) Sore Sore Sore Sore Sore Sore Sore Sore					
Product Characteristics Solor WHTE (Opaque Body), BROWN (Opaque Cap) Score no score hape CAPSULE Size 18mm lavor Imprint Code NZ791;75mg Sontains Imprint Code NZ791;75mg Packaging Imprint Code NZ791;75mg Packaging Marketing Start Date Marketing End Da NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 OS NDC:40032-791-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Marketing End Da NDC:40032-791-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Marketing End Da NDC:40032-791-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Marketing End Da Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Da NDA ANDA204445 05/28/2015 Marketing End Da OXXYCYCLINE HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Rate of Administration GRAL ORAL Marketing Code (Source)	BROWN IRON OXIDE (UN	(UNII: WZH3C48 M4T)			
Non- WHITE (Opaque Body), BROWN (Opaque Cap) Score no score hape CAPSULE Size 18 mm lavor Imprint Code Imprint Code NL791,75mg contains Imprint Code Marketing Start Date Marketing End Date Ackaging Item Code Package Description Marketing Start Date Marketing End Date NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Item Code NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDA Application Number or Monograph Citation Marketing Start Date Marketing End Date Norketing End Date NDA AnDA20444 ANDA204445 05/28/2015 Item Code (Source) NDC:40032-792 Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 State of Admi		I: 1N032N7MFO)			
Non- WHITE (Opaque Body), BROWN (Opaque Cap) Score no score hape CAPSULE Size 18 mm lavor Imprint Code Imprint Code NL791,75mg contains Imprint Code Marketing Start Date Marketing End Date Ackaging Item Code Package Description Marketing Start Date Marketing End Date NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Item Code NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDA Application Number or Monograph Citation Marketing Start Date Marketing End Date Norketing End Date NDA AnDA20444 ANDA204445 05/28/2015 Item Code (Source) NDC:40032-792 Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 State of Admi					
Non- WHITE (Opaque Body), BROWN (Opaque Cap) Score no score hape CAPSULE Size 18 mm lavor Imprint Code Imprint Code NL791,75mg contains Imprint Code Marketing Start Date Marketing End Date Ackaging Item Code Package Description Marketing Start Date Marketing End Date NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Item Code NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Item Code Marketing End Date NDA Application Number or Monograph Citation Marketing Start Date Marketing End Date Norketing End Date NDA AnDA20444 ANDA204445 05/28/2015 Item Code (Source) NDC:40032-792 Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 State of Admi	Product Characterist	ics			
Invar Imprint Code NL791;75mg Invariants Imprint Code NL791;75mg Packaging Imprint Code NL791;75mg Item Code Package Description Marketing Start Date Marketing End Date NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Imprint Code Imprint Code NDC:40032-791-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Imprint Code Imprint Code Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 Imprint Code Imprint Code VCXYCYCLINE HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792				Score	no score
Contains Item Code Package Description Marketing Start Date Marketing End Date NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Image: Containing Containin Containing Containing Containing Containing Containing Contain	hape CAPSULE			Size	18 mm
Packaging Item Code Package Description Marketing Start Date Marketing End Date NDC:40032-791-11 50 in 1BOTTLE; Type 0: Not a Combination Product 05/28/2015 05/28/2015 NDC:40032-791-01 100 in 1BOTTLE; Type 0: Not a Combination Product 05/28/2015 05/28/2015 NDC:40032-791-01 100 in 1BOTTLE; Type 0: Not a Combination Product 05/28/2015 05/28/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 05/28/2015 05/28/2015 OXYCYCLLINE	lavor			Imprint Code	NL791;75m
Item CodePackage DescriptionMarketing Start DateMarketing End DateNDC:40032-791-1150 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015NDC:40032-791-10100 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015Marketing InformationMarketing Start DateMarketing End DateMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateNDAANDA20444605/28/2015Marketing End DateProduct InformationHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:40032-792	Contains				
Item CodePackage DescriptionMarketing Start DateMarketing End DateNDC:40032-791-1150 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015NDC:40032-791-10100 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015Marketing InformationMarketing Start DateMarketing End DateMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateNDAANDA20444605/28/2015Marketing End DateProduct InformationHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:40032-792					
Item CodePackage DescriptionMarketing Start DateMarketing End DateNDC:40032-791-1150 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015NDC:40032-791-01100 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015NDC:40032-791-101000 in 1 BOTTLE; Type 0: Not a Combination Product05/28/201505/28/2015Marketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateNDAANDA20444605/28/201505/28/201505/28/2015OXYCYCLINE Doxycycline capsuleProduct InformationHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:40032-792Route of AdministrationORAL	ackaging				
NDC:40032-791-11 50 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 NDC:40032-791-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 NDC:40032-791-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 OXYCYCLINE OXYCYCLINE OXYCYCLINE OXYCYCLINE OXYCYCLINE OXYCYCLINE OXAL MUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration		Package Description	Market	ting Start Date	Marketing En
NDC:40032-791-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 05/28/2015	NDC:40032-791-11 50 ir			-	0
Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 05/28/2015 OXYCYCLINE Doxycycline capsule HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL ORAL ORAL	NDC:40032-791-01 100	n 1 BOTTLE; Type 0: Not a Combination Produc	t 05/28/20	15	
Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 OXYCYCLINE OXYCYCLINE OXYCYCLINE Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Soute of Administration	NDC:40032-791-10 1000	in 1 BOTTLE; Type 0: Not a Combination Produ	ct 05/28/20	15	
Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 OXYCYCLINE OXYCYCLINE OXYCYCLINE Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Soute of Administration					
Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA204446 05/28/2015 OXYCYCLINE OXYCYCLINE OXYCYCLINE Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Soute of Administration					
NDA ANDA204446 05/28/2015 OOXYCYCLINE OOXYCYCLINE Product Information Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration	-				
POXYCYCLINE poxycycline capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL				-	Marketing End
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL	ANDA AI	IDA204446	05/28/20	15	
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL					
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL	OXYCYCLINE				
Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL	oxycycline capsule				
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:40032-792 Route of Administration ORAL	•				
Route of Administration ORAL	Product Information				
Route of Administration ORAL	Product T ype	HUMAN PRESCRIPTION DRUG	Ite m Co	ode (Source)	NDC:40032-7
	Route of Administration				
active Ingredient/Active Moiety		ORAL			
Active Ingredient/Active Moiety		ORAL			
		ORAL			

	Ingredient Name						
SILICON DIO	D XIDE (U	NII: ETJ7Z6XBU4)					
MAGNESIUM	I STEAR	TE (UNII: 70097M6130)					
		CRYSTALLINE (UNII: OP1R32D61U)					
SODIUM ST	ARCH GL	YCOLATE TYPE A POTATO (UNII: 5856J3G2A2)					
		XIDE (UNII: XM0 M8 7F357)					
		UNII: 1K09F3G675)					
		OW (UNII: EX438O2MRT)					
		II: PN2ZH5LOQY)					
) (UNII: 35SW5USQ3G)					
		UNII: 15FIX9V2JP)					
GELATIN (U		QN327L) LFATE (UNII: 368GB5141J)					
SHELLAC (U							
		XIDE (UNII: WZH3C48 M4T)					
BRO WN IRO	N O XIDE	(UNII: 1N032N/MFO)					
BRO WN IRO Product C	haracte	eristics		Saava			
BROWN IRO Product C Color	haracte YELLC	e ristics W (Opaque Body) , BROWN (Opaque Cap)		Score		io score 9mm	
BROWN IRO Product C Color Shape	haracte	e ristics W (Opaque Body) , BROWN (Opaque Cap)		Size	1	9mm	
BROWN IRO Product C Color	haracte YELLC	e ristics W (Opaque Body) , BROWN (Opaque Cap)			1		
BROWN IRO Product C Color Shape Flavor	haracte YELLC	e ristics W (Opaque Body) , BROWN (Opaque Cap)		Size	1	9mm	
BROWN IRO Product C Color Shape Flavor	haracte YELLC CAPSU	e ristics W (Opaque Body) , BROWN (Opaque Cap)		Size	1	9mm	
BROWN IRO Product C Color Shape Flavor Contains	haracte YELLC CAPSU	e ristics W (Opaque Body) , BROWN (Opaque Cap)		Size	1 N	9mm NL792;100mg	
BROWN IRO Product C Color Shape Flavor Contains Packaging # Item (haracte YELLC CAPSU	e ristics W (Opaque Body), BROWN (Opaque Cap) ILE		Size Imprint Code ting Start Date	1 N	9mm NL792;100mg	
BROWNIRO Product C Color Shape Flavor Contains Packaging # Item (1 NDC:4003)	haracte YELLC CAPSU	eristics W (Opaque Body), BROWN (Opaque Cap) ILE Package Description	Marke	Size Imprint Code ting Start Date	1 N	9mm NL792;100mg	
BROWNIRO Product C Color Shape Flavor Contains Packaging # Item (1 NDC:4003: 2 NDC:4003:	haracte YELLC CAPSU	Pristics W (Opaque Body), BROWN (Opaque Cap) ILE Package Description 50 in 1 BOTTLE; Type 0: Not a Combination Product	Marke 0 5/28/20	ting Start Date	1 N	9mm NL792;100mg	
BROWN IRO	haracta YELLC CAPSU CODE 2-792-11 2-792-12 2-792-10	Package Description Package Description 50 in 1 BOTTLE; Type 0: Not a Combination Product 250 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product	Marke 05/28/20 05/28/20	ting Start Date	1 N	9mm NL792;100mg	
BROWN IRO Color Shape Flavor Contains Packaging # Item (1 NDC:4003: 2 NDC:4003: 3 NDC:4003:	haracta YELLC CAPSU Code 2-792-11 2-792-12 2-792-10 ng Inf	eristics W (Opaque Body) , BROWN (Opaque Cap) ILE Package Description 50 in 1 BOTTLE; Type 0: Not a Combination Product 250 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product	Marke 05/28/20 05/28/20	Size Imprint Code ting Start Date 015 015 015	Mar	9mm NL792;100mg keting End Da	
BROWN IRO	haracta YELLC CAPSU Code 2-792-11 2-792-12 2-792-10 ng Inf	eristics W (Opaque Body) , BROWN (Opaque Cap) ILE Package Description 50 in 1 BOTTLE; Type 0: Not a Combination Product 250 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product	Marke 05/28/20 05/28/20	ting Start Date 115 115 115 115 115 115 115	Mar	9mm NL792;100mg	

Establishmen	t		
Name	Address	ID/FEI	Business Operations
Novel Laboratories, Inc.		793518643	ANALYSIS(40032-790, 40032-791, 40032-792), MANUFACTURE(40032-790, 40032-791, 40032-792)

Revised: 12/2019

Novel Laboratories, Inc.